Trials / Completed
CompletedNCT00171184
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- —
Summary
The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged \>Ý 65 years with OAB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darifenacin | Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily |
| DRUG | Placebo | Placebo tablet once daily with sham titration |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-06-01
- First posted
- 2005-09-15
- Last updated
- 2017-05-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00171184. Inclusion in this directory is not an endorsement.